Global and USA Cancer Immunotherapy Market Eyes on Revenue Excess of $80 Billion, Finds New Report
The new report named Global & USA Cancer Immunotherapy Market Analysis to 2020" reveals that the cancer immunotherapy space will bea significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers' Yervoy drug for melanoma (2011) and Dendreon'sProvenge(2010) for prostate cancer. Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid,...
View full press release